Alaunos Therapeutics (Nasdaq:TCRT) - Stock Analysis

NodeGuardian · 2026-04-12T17:52:24+00:00

This analysis reviews Alaunos Therapeutics, a cell therapy company with a $6.7m market cap. It highlights its earnings growth, current share price of $2.98, and risks like cash limitations and past dilution.

NodeGuardian

2026-04-12 17:52:24

Abstract generation in progress

This Simply Wall St analysis provides an overview of Alaunos Therapeutics (Nasdaq:TCRT), a clinical-stage oncology-focused cell therapy company with a market cap of US$6.7m. The report details its financials, including a current share price of US$2.98, recent news, and performance metrics. While the company has shown earnings growth, it faces risks such as a limited cash runway and past shareholder dilution.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

Reward
like
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
Gate13thAnniversaryDr.HanLetter
38.68K Popularity
#
CryptoMarketsDipSlightly
169.61K Popularity
#
USBlocksStraitofHormuz
710.26K Popularity
#
AaveDAOApproves$25MGrant
1.8M Popularity
#
GateSquareAprilPostingChallenge
1.63M Popularity

Sitemap

Alaunos Therapeutics (Nasdaq:TCRT) - Stock Analysis

Trending Topics

Gate13thAnniversaryDr.HanLetter

CryptoMarketsDipSlightly

USBlocksStraitofHormuz

AaveDAOApproves$25MGrant

GateSquareAprilPostingChallenge

Pin